SCHOTT announces the rebranding of its glass syringes

NewsGuard 100/100 Score

The international technology group SCHOTT announced the rebranding of its glass syringes, now known as syriQTM (previously forma 3s). The new name comes on the heels of growth in the field of prefillable syringes, and represents SCHOTT’s renewed commitment to delivering high quality pharmaceutical packaging. SCHOTT will display its syriQTM product line at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in San Antonio, Texas on November 11 to 14, 2013 at booth #4209.

SCHOTT emphasizes growth targets of its global syringe business and launched a new brand to resonate this new vision: All glass syringes are now marketed under the umbrella of the new brand name syriQ (TM).

SCHOTT emphasizes the growth prospects of its global syringe business. The company presented its new brand appearance at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in San Antonio, Texas.

“It has always been our strategy to engage in open dialogues with our customers,” said Dr. Jürgen Sackhoff, Executive Vice President of SCHOTT Pharmaceutical Systems. “Integrating with their processes enables us to discover the best solutions. We’ll continue this collaboration under the syriQ brand with a new vision for further innovations, especially in the area of prefillable glass syringes.”

SCHOTT has been manufacturing glass and polymer syringes in Europe and the U.S. for more than 12 years and recently doubled its production capacities for TopPac polymer syringes. The production facility in St. Gallen, Switzerland is a center of excellence, harboring a top-notch on site R&D team and maintaining a large annual production capacity to ensure security of supply. The factory also houses the infrastructure needed for further expansion.

To offer pharmaceutical companies a broad range of solutions, SCHOTT holds a complete portfolio of both glass and polymer syringes. In the field of glass syringes, the offerings range from 0.5 to 3 milliliter (ml) products, suitable for a variety of applications, such as heparin, vaccines, biotechnology, and special applications. With regard to polymer syringes, the company has completed its portfolio of large volume syringes for intensive care, which now includes the entire range of 10 ml, 20 ml, and 50 ml formats.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
FDA-approved surgical robots trend toward autonomy, study finds